S
Sandhya Bawa
Researcher at Jamia Hamdard
Publications - 55
Citations - 1767
Sandhya Bawa is an academic researcher from Jamia Hamdard. The author has contributed to research in topics: Antibacterial activity & Monoacylglycerol lipase. The author has an hindex of 16, co-authored 54 publications receiving 1409 citations. Previous affiliations of Sandhya Bawa include Hamdard University.
Papers
More filters
Journal ArticleDOI
A review on anticancer potential of bioactive heterocycle quinoline.
TL;DR: This review has compiled and discussed specifically the anticancer potential of quinoline derivatives, which could provide a low-height flying bird's eye view of theQuinoline derived compounds to a medicinal chemist for a comprehensive and target oriented information for development of clinically viable anticancer drugs.
Journal ArticleDOI
Biological activities of quinoline derivatives.
TL;DR: An in depth view of work done so far on quinolines and its biological activities covering anticancer, antimycobacterial, antimicrobial, anticonvulsant, antiinflamatory and cardiovascular activities is provided.
Journal ArticleDOI
Biological activities of pyrazoline derivatives--a recent development.
TL;DR: The present review provides an insight view to pyrazolines synthesis and its biological activities along with the compilation of recent patents on pyrazoline derivatives.
Journal ArticleDOI
Structural modifications of quinoline-based antimalarial agents: Recent developments.
TL;DR: Various chemical modifications of quinoline have been attempted to achieve analogs with potent antimalarial properties against sensitive as well as resistant strains of Plasmodium sp.
Journal ArticleDOI
Antidepressant potential of nitrogen-containing heterocyclic moieties: An updated review.
Nadeem Siddiqui,Andalip,Sandhya Bawa,Ruhi Ali,Obaid Afzal,M. Jawaid Akhtar,Bishmillah Azad,Rajesh Kumar +7 more
TL;DR: Reviews of literature suggest that heterocyclic moieties and their derivatives has proven success in treating depression, and restrictions on their use have caused controversy and off-label prescription a risk, despite claims of superior efficacy.